Skip to main content
OpenTrials
Completed

NCT Number: NCT04926961

Testing the Contribution of Orbitofrontal Cortex Networks to Reward Identity Learning

This research study examines the contribution of orbitofrontal cortex (OFC) networks to learning reward identity expectations.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Northwestern University

Chicago, Illinois, 60611, United States

About this study

This study is designed to examine the contribution of OFC networks to reward identity learning. It will use network-targeted TMS to test whether OFC is necessary for reward identity learning. Healthy human subjects will perform a three-reward reversal learning task after either TMS or sham stimulation while fMRI data are acquired. This is a randomized, within-subject, cross-over study.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age between 18 and 50 years old
  • Right-handed
  • Fluent English speakers

Exclusion criteria

  • History of significant neurological conditions (e.g., epilepsy, dementia, multiple sclerosis, brain tumors, etc.)
  • History of major psychiatric conditions (e.g., general anxiety disorder, depression, schizophrenia, obsessive-compulsive disorder, post-traumatic stress disorder, attention deficit hyperactivity disorder, alcoholism, etc.)
  • Significant medical illnesses (e.g., cancer, meningitis, chronic obstructive pulmonary disease, cardiovascular disease, etc.)
  • Significant cerebrovascular risk factors (e.g., hypertension, diabetes, elevated cholesterol, etc.)
  • Current use of psychoactive medications (e.g., barbiturates, benzodiazepines, chloral hydrate, haloperidol, lithium, carbamazepine, phenytoin, citalopram, escitalopram, fluoxetine, diazepam, etc.)
  • Smell or taste dysfunction
  • History of significant allergies requiring hospitalization for treatment
  • History of severe asthma requiring hospitalization for treatment
  • Habitual smoking
  • Magnetic implants (e.g., shunts or stents, aneurysm clips, surgical clips, cochlear implants, metal bone/joint pins, plates and screws, eyelid spring or wires, etc.)
  • Electronic devices (e.g., implanted cardiac defibrillator, cardiac pacemaker, deep brain/spinal cord or nerve stimulator, internal electrodes/wires, medication infusion devices, etc.)
  • History of metal working without proper eye protection, or injury with metal shrapnel or metal slivers
  • Claustrophobia
  • Pregnancy
  • Predisposition to seizures (e.g., personal history of seizures, family history of seizures epilepsy, pregnancy, alcoholism, etc.)
  • Use of medications that increase the likelihood of seizures (e.g., bupropion, citalopram, duloxetine, ketamine, gamma-hydroxybutyrate, etc.)
  • History of surgical procedures performed on the brain or spinal cord
  • History of severe head trauma followed by loss of consciousness
  • History of fainting spells or syncope
  • Hearing problems or tinnitus

Treatment and study plan

Sham Transcranial Magnetic Stimulation (TMS)

Device

Sham TMS will be applied using the MagVenture MagPro X100 stimulator with the placebo side of the Cool-B65 A/P coil.

Real transcranial magnetic stimulation (TMS)

Device

Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil.

Primary outcomes

  1. Percentage of correct outcome predictions

    Time frame: 1 hour

    Percentage of correct outcome predictions in response to predictive cues during the reversal learning task.

  2. Blood oxygen level-dependent (BOLD) responses

    Time frame: 1 hour

    Blood oxygen level-dependent (BOLD) responses measured using functional magnetic resonance imaging (fMRI) during the reversal learning task.

Sponsors and collaborators

Lead sponsor

Northwestern University

Other

Registry information

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Jun 15, 2021
Registry last updated
Jun 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.